Apolipoprotein M Gene Polymorphism Rs805297 (C-1065A): Association With Type 2 Diabetes Mellitus and Related Microvascular Complications in South Egypt

Tageldeen, Manal Mohammed; Badrawy, Hosny; Abdelmeguid, Mona; Zaghlol, Mohammed; Gaber, Noha; Kenawy, Eglal M

doi:10.1016/j.amjms.2021.02.002

Cited by 5 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two hundred eighty-five patients were evaluated in our research, and proteinuriawas seen in 114 patients (40%).This is per other studies, which have also shown proteinuria as a common complication. [11][12][13][14][15] Multiple studies have been performed worldwide to know the exact prevalence of proteinuria in diabetic patients at the time of presentations. In one study, it appeared to be25.6% [16], while in another study, it was 57.44%.…”

Section: Discussionmentioning

confidence: 99%

Frequency of Proteinuria in Newly Diagnosed Diabetic Patients

Rahman¹,

Babar²,

Sebtain³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Introduction: Diabetes mellitus is a huge global health issue, affecting more than 350 million people worldwide, and the number might rise to 439 million in 2030. Diabetes Mellitus is associated with many complications. Most of these complications usually develop after many years or even decades of exposure to chronic hyperglycemia. Diabetic Nephropathy is one of the most common and grave complication of diabetes mellitus and is associated with increased morbidity and mortality. Study Design: A cross-sectional study was performed on 285 patients from August 2021 to February 2022 on all newly diabetic patients in Hayatabad Medical Complex, Peshawar. Their 24-hour urine for protein analysis was measured to screen them for proteinuria.After measuring the urine protein level in each patient, the study's total frequency was computed across all the patients who had been diagnosed. Data was recorded into a proforma. Results: The age range in this study was from 15 to 70 years with a mean age of 43.01±6.90 years, mean BMI was 27.67±1.99 Kg/m2, and mean proteinuria levels were 42.38±34.142mg/ dl. Males constituted the majority of the patient-group (62.1%). 34.7% of patients were also hypertensive. Proteinuria was seen in 114 patients (40%). Conclusion: This study has concluded that screening for the complications of diabetic patients is beneficial in the preventive management of the disease. Keywords: Diabetic patients, proteinuria

show abstract

Section: Discussionmentioning

confidence: 99%

Frequency of Proteinuria in Newly Diagnosed Diabetic Patients

Rahman¹,

Babar²,

Sebtain³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…Therefore, a recent study performed a Mendelian randomization analysis applied to two Danish cohorts but could not support causality between genetic determined reduction in apoM and risk of T2D [49]. Other studies suggest otherwise and stress the point that associations between apoM and T2D may be influenced by other confounding factors such as ethnicity [50,51]. Further studies will be important to unravel the mechanistic role of apoM, but also S1P and the apoM/S1P-complex.…”

Section: Apom/s1p and Metabolic Disturbances Affecting Lipid Metabolismmentioning

confidence: 98%

Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system

Mattisson

Christoffersen

2021

Atherosclerosis

View full text Add to dashboard Cite

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with highdensity lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/ S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1Psignaling may be beneficial to patients with cardiovascular and inflammatory diseases.

show abstract

“…140,144 In South Egyptians population, ApoM rs805297 (À1065C/A) polymorphism influence the T2DM susceptibility (Table 1). 145…”

Section: Drug Transportermentioning

confidence: 99%

Effect of genetic variations in drug transporters, metabolizing enzyme and regulatory genes on the development of HIV‐associated lipodystrophy

Shyamveer

Arif

Singh

2023

The Journal of Gene Medicine

View full text Add to dashboard Cite

Adipocytes play a crucial role in the metabolism of lipids and sugars. Their response varies depending on the circumstances or other factors influenced by physiological and metabolic stresses. People living with HIV (PLWH) experience different effects of HIV and highly active antiretroviral therapy (HAART) on their body fat. Some patients respond well to antiretroviral therapy (ART), while others taking similar regimens do not. The genetic makeup of patients has been strongly linked to the variable responses to HAART among PLWH. The cause of HIV-associated lipodystrophy syndrome (HALS) is not well understood, but it may be influenced by genetic variations in the host. The metabolism of lipid effectively modulates plasma triglyceride and high-density lipoprotein cholesterol levels in PLWH. Genes related to drug metabolism and transport play an important role in the transportation and metabolism of ART drugs. Genetic variation in metabolizing enzyme genes of antiretroviral drugs, lipid transport and transcription factor-related genes could interfere with fat storage and metabolism, contributing to the development of HALS. Hence we examined the impact of genes associated with transport, metabolism and various transcription factors in metabolic complications, and their impact on HALS. A study using databases such as PubMed, EMBASE and Google Scholar was conducted to understand the impact of these genes on metabolic complications and HALS. The present article discuss the changes in the expression and regulation of genes and their involvement in the lipid metabolism, lipolysis and lipogenesis pathways. Moreover, alteration of the drug transporter, metabolizing enzyme and various transcription factors can lead to HALS. Single-nucleotide polymorphisms in genes that play an essential role in drug metabolism and drug and lipid transportation may also contribute to individual differences in the emergence of metabolic and morphological alterations during HAART treatment.

show abstract

Apolipoprotein M Gene Polymorphism Rs805297 (C-1065A): Association With Type 2 Diabetes Mellitus and Related Microvascular Complications in South Egypt

Cited by 5 publications

References 31 publications

Frequency of Proteinuria in Newly Diagnosed Diabetic Patients

Frequency of Proteinuria in Newly Diagnosed Diabetic Patients

Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system

Effect of genetic variations in drug transporters, metabolizing enzyme and regulatory genes on the development of HIV‐associated lipodystrophy

Contact Info

Product

Resources

About